6696.TWO Lin BioScience Inc.

Healthcare Biotechnology Taiwan OTC Exchange
145.00 TWD
Close of Nov 5, 2026
24.75 207.00
Market cap
TWD 120B
P/E
-
P/B
12.41x
ROE
-12.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 6696.TWO undervalued?

Graham number

The Graham number of Lin BioScience Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Lin BioScience Inc. fundamental analysis

No fundamental analysis for Lin BioScience Inc. yet.

Lin BioScience Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Lin BioScience Inc.

Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor …

Full company profile